Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

SUNNYVALE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiological criteria that put them at high risk of complications from more invasive surgical procedures.

Silk Road Medical Announces FDA Approval of Expanded Indications for the ENROUTE® Transcarotid Stent System

SUNNYVALE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2022 Healthcare Conference.

Silk Road Medical to Present at the BofA Securities 2022 Healthcare Conference

SUNNYVALE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report First Quarter 2022 Financial Results on May 4, 2022

Calgary, Alberta--(Newsfile Corp. - April 13, 2022) - Silk Road Energy Inc. (TSXV: SLK.H) reports that it has finalized its 2022 exploration program for its 100 percent-owned Amikougami gold property in Kirkland Lake, Ontario.The company anticipates commencing its 2022 field program in August subject to the availability of a drilling rig, personnel and field equipment.The company is planning to drill five "short" diamond drill-holes to 75 metre depths to establish the nature of the mineralization...

Silk Road Unveils Kirkland Lake Exploration Plan

Silk Road Medical has seen its premium valuation come down quite a bit over the past year.

Silk Road Medical - What A Road It Has Been

Silk Road Medical, Inc (SILK) CEO Erica Rogers on Q4 2021 Results - Earnings Call Transcript

SUNNYVALE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2021.

Silk Road Medical Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Financial Outlook

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Silk Road Medical (SILK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SUNNYVALE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

SUNNYVALE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the 11th Annual SVB Leerink Global Healthcare Conference.

Silk Road Medical to Present at the 11th Annual SVB Leerink Global Healthcare Conference

The heavy selling pressure might have exhausted for Silk Road Medical (SILK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Silk Road Medical (SILK) Loses 32.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SUNNYVALE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Silk Road Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

SUNNYVALE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Silk Road Medical to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q3 2021 Results - Earnings Call Transcript

Silk Road Medical (SILK) delivered earnings and revenue surprises of -29.03% and -5.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q3 Loss, Lags Revenue Estimates

SUNNYVALE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended September 30, 2021.

Silk Road Medical Reports Third Quarter 2021 Financial Results

SUNNYVALE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Stifel 2021 Virtual Healthcare Conference.

Silk Road Medical to Present at the Stifel 2021 Virtual Healthcare Conference

Will Silk Road Medical (SILK) Report Negative Earnings Next Week? What You Should Know

SUNNYVALE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Third Quarter 2021 Financial Results on November 9, 2021

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Silk Road Medical (SILK).

Is Silk Road Medical (SILK) a Great Growth Stock?

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Silk Road Medical (SILK) Upgraded to Buy: Here's Why

SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

Silk Road Medical to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Large-Scale Analysis of TCAR in The Treatment of Standard Surgical Risk Patients Presented at The Society for Vascular Surgery 2021 Vascular Annual Meeting

First Ever Analysis of TCAR in Standard Surgical Risk Patients Demonstrates Clinical Benefits in Large Comparative Dataset

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q2 2021 Results - Earnings Call Transcript

The stock price of Silk Road Medical Inc (NASDAQ: SILK) increased by over 16% during intraday trading. This is why it happened.

News for Silk Road Medical Inc Stock (SILK)